Skip to main content

Newsroom

Press Releases

February 13, 2017
GAITHERSBURG, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5 million to develop monoclonal antibody therapeutics for viral h...

 


Corporate Headquarters Ribbon Cutting

Featured Stories

BETHESDA, MD - The International Biomedical Research Alliance today announced…

MORE

Soligenix, Inc. Announced today that it has extended its development agreement with Emergent…

MORE

Emergent BioSolutions, a Gaithersburg-based drug developer, has signed a contract with the…

MORE

Featured Stories

BETHESDA, MD - The International Biomedical Research Alliance today announced…

MORE

Soligenix, Inc. Announced today that it has extended its development agreement with Emergent…

MORE

Emergent BioSolutions, a Gaithersburg-based drug developer, has signed a contract with the…

MORE

Media
Tracey Schmitt Lintott
schmittt@ebsi.com 
TEL 240-631-3394 

Investors
Robert Burrows 
burrowsr@ebsi.com 
TEL 240-631-3280